Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akeso Biopharma
Pharma
PD-1 bispecifics, Enhertu, Regeneron-Hansoh—Fierce Pharma Asia
The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal.
Angus Liu
Jun 6, 2025 7:15am
Summit shares results from ivonescimab's first global ph. 3 trial
May 30, 2025 9:04am
Akeso, AstraZeneca, Ono—Fierce Pharma Asia
May 2, 2025 7:58am
Akeso CEO tries to reset expectations of bispecific's OS readout
Apr 28, 2025 6:50am
Summit stock falls as Akeso shares bispecific OS data vs. Keytruda
Apr 25, 2025 4:02pm
Akeso’s Anniko enters crowded US PD-1 market
Apr 25, 2025 10:55am
